


**Table S1. Catalog Numbers for Reagents Used**

<b>Silencer Select siRNA Oligos</b>		
<b>Gene</b>	<b>Catalog #</b>	<b>Manufacturer</b>
Negative Control	4390843	Ambion/ ThermoFisher
HDAC8 #1	s31698	Ambion/ ThermoFisher
HDAC8 #2	s31697	Ambion/ ThermoFisher
HDAC9 #1	s18775	Ambion/ ThermoFisher
HDAC9 #2	s18774	Ambion/ ThermoFisher
FFAR2	s223804	Ambion/ ThermoFisher
FFAR3	s230084	Ambion/ ThermoFisher
HCAR2	s50344	Ambion/ ThermoFisher
HDAC1	s73	Ambion/ ThermoFisher
HDAC2	s6493	Ambion/ ThermoFisher
HDAC3	s16878	Ambion/ ThermoFisher
<b>BD OptEIA ELISA Kits</b>		
<b>Target</b>	<b>Catalog #</b>	<b>Manufacturer</b>
IL-6	BDB555220	BD Biosciences
IL-8	BDB555244	BD Biosciences
<b>Taqman Gene Expression Assays</b>		
<b>Gene</b>	<b>Catalog #</b>	<b>Manufacturer</b>
GAPDH	Hs99999905_m1	ABI/ ThermoFisher
HDAC1	Hs02621185_s1	ABI/ ThermoFisher
HDAC2	Hs00231032_m1	ABI/ ThermoFisher
HDAC3	Hs00187320_m1	ABI/ ThermoFisher
HDAC4	Hs01041638_m1	ABI/ ThermoFisher
HDAC5	Hs00608366_m1	ABI/ ThermoFisher
HDAC6	Hs00195869_m1	ABI/ ThermoFisher
HDAC7	Hs00248789_m1	ABI/ ThermoFisher
HDAC8	Hs00954353_g1	ABI/ ThermoFisher
HDAC9	Hs00206843_m1	ABI/ ThermoFisher
HDAC10	Hs00368899_m1	ABI/ ThermoFisher
HDAC11	Hs00978041_m1	ABI/ ThermoFisher
FFAR2	Hs00271142_s1	ABI/ ThermoFisher
FFAR3	Hs02519193_g1	ABI/ ThermoFisher
HCAR2	Hs02341584_s1	ABI/ ThermoFisher
IL-1beta	Hs00174097_m1	ABI/ ThermoFisher
IL-6	Hs00985639_m1	ABI/ ThermoFisher
IL-8	Hs00174103_m1	ABI/ ThermoFisher
TNFalpha	Hs00174128_m1	ABI/ ThermoFisher
TSLP	Hs00263639_m1	ABI/ ThermoFisher
CXCL2	Hs00601975_m1	ABI/ ThermoFisher
CXCL10	Hs00171042_m1	ABI/ ThermoFisher


## Supplemental Figure 1.




1 Supplemental Figure 1. Inhibition of HDAC activity in sebocytes by short-chain fatty  
2 acids. HDAC activity was measured in nuclear extracts of SEB-1 sebocytes (A-C) or SZ95  
3 sebocytes (D-F) incubated with increasing concentrations of Trichostatin A (A,D), propionate  
4 (B,E) or butyrate (C,F). HDAC activity was calculated as percentage of control (untreated)  
5 extracts for each cell type. Data shown are mean +/- SEM of one experiment representative of  
6 two independent experiments with n=2 for each condition. \*p<0.05; \*\*p<0.01; \*\*\*p<0.001 as  
7 determined by one-way ANOVA.

## Supplemental Figure 2.


### A. HDAC8 Silencing




### B. HDAC8 Silencing



### C. HDAC9 Silencing



### D. HDAC9 Silencing




1

2 **Supplemental Figure 2. HDAC8 and HDAC9 depletion by siRNA.** SEB-1 sebocytes were  
3 treated with siRNA specific for HDAC8 or HDAC9 as described in the Materials and Methods  
4 section. Western blots were performed to measure the protein-level depletion of HDAC8 (A,B)  
5 and HDAC9 (C,D) and densitometry analysis was used to calculate the efficiency of knockdown  
6 relative to control siRNA-treated cells. Data is representative of three independent experiments.

7

### Supplemental Figure 3.



1

### 2 Supplemental Figure 3. Additional siRNA oligonucleotides used for depletion of HDAC8

3 and HDAC9 in sebocytes enhance cytokine response. SEB-1 sebocytes were treated with

4 siRNA oligonucleotides specific for HDAC8 or HDAC9, or a negative control. A) Measurement

5 of HDAC8 and HDAC9 expression levels, normalized to GAPDH levels, following treatment

6 with siRNA. B-C) Expression levels of IL-6 and IL-8 from sebocytes treated with the TLR2/6

7 ligand MALP-2 following siRNA-mediated depletion of HDAC8 or HDAC9 (transcript

8 abundances normalized to GAPDH). For graphs, data shown is mean +/- SEM for one

9 experiment representative of three independent experiments with n=3 for each condition.

10 \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$  as determined by two-way ANOVA.

11

12